e-learning
resources
Amsterdam 2015
Wednesday, 30.09.2015
Emerging technologies for malignant pleural diseases management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: In-vitro study
Giulia Stella (Pavia, Italy), Giulia Stella, Emanuela Cova, Simona Inghilleri, Davide Piloni, Miriam Colombo, Simona Mrakic-Sposta, Laura Pandolfi, Angelo Corsico, Ymera Pignochino, Davide Prosperi, Patrizia Morbini, Federica Meloni
Source:
International Congress 2015 – Emerging technologies for malignant pleural diseases management
Session:
Emerging technologies for malignant pleural diseases management
Session type:
Oral Presentation
Number:
5003
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Giulia Stella (Pavia, Italy), Giulia Stella, Emanuela Cova, Simona Inghilleri, Davide Piloni, Miriam Colombo, Simona Mrakic-Sposta, Laura Pandolfi, Angelo Corsico, Ymera Pignochino, Davide Prosperi, Patrizia Morbini, Federica Meloni. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: In-vitro study. Eur Respir J 2015; 46: Suppl. 59, 5003
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Intrapleural photodynamic therapy for malignant pleural mesothelioma: A new dosimetry approach
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016
Volume quantification of malignant pleural mesothelioma
Source: International Congress 2015 – Malignant pleural effusions and mesothelioma
Year: 2015
Detection of EpCAM-positive microparticles in pleural fluid: A new approach for the diagnosis of the tumoral origin of pleural effusions
Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management
Year: 2015
Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016
Role of tumor derived versican in experimental malignant pleural mesothelioma
Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside
Year: 2016
Malignant pleural mesothelioma: A retrospective analysis of 32 cases
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
A conditional mouse model of malignant pleural mesothelioma
Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside
Year: 2016
Treatment of malignant pleural mesothelioma: dilemmas
Source: Eur Respir J 2005; 26: Suppl. 49, 73s
Year: 2005
Outcomes of bedside talc slurry pleurodesis for malignant pleural effusions: A retrospective analysis
Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases
Year: 2013
Chemotherapy for treatment of malignant pleural mesothelioma
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004
Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma
Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies
Year: 2013
Effect of asbestos on gene expression of tight junctions components in malignant pleural mesothelioma
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016
Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells
Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Year: 2018
Talc pleurodesis for malignant pleural effusion - effect on survival: Case-control follow-up study
Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma
Year: 2014
Malignant mesothelioma vs metastatic carcinoma of pleura: Do pathology and radiology agree?
Source: Annual Congress 2013 –Morphologic imaging
Year: 2013
Pleural mesothelioma with solitary simultaneous subcutaneous tissue metastasis of the abdominal wall at diagnosis - First clinical documentation
Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases
Year: 2013
Management of malignant pleural mesothelioma
Source: Hands-on Course 2013 - Medical Thoracoscopy
Year: 2013
Novel therapeutic strategies against malignant pleural mesothelioma by selumetinib-loaded targeted nanoparticles.
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Management of malignant pleural mesothelioma
Source: Hands-on Course 2012 - Medical Thoracoscopy
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept